Prognosis of patients with peripheral arterial disease

Journal of Cardiovascular Surgery

Volumn 50, Issue 1, 2009, Pages 109-121

  Welten, G M J M ^a   Schouten, O ^a   Chonchol, M ^b   Hoeks, S E ^a   Bax, J J ^c   Van Domburg, R T ^a   Poldermans, D ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF COLORADO   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Coronary artery disease; Peripheral vascular diseases; Prognosis; Surgical procedures, operative; Treatment outcome

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PENTOXIFYLLINE; PLACEBO; THIAZIDE DIURETIC AGENT; TROPONIN; URIC ACID;

ANKLE BRACHIAL INDEX; ATHEROSCLEROSIS; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLAUDICATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DIABETES MELLITUS; DIGESTIVE SYSTEM ULCER; DRUG MECHANISM; DRUG SAFETY; ENDOVASCULAR SURGERY; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; LUNG DISEASE; NON INVASIVE MEASUREMENT; PERIOPERATIVE COMPLICATION; PERIPHERAL VASCULAR DISEASE; POLYVASCULAR DISEASE; POSTOPERATIVE COMPLICATION; PREVALENCE; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURGICAL TECHNIQUE; TREATMENT RESPONSE; VASCULAR DISEASE;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; HUMANS; PERIPHERAL VASCULAR DISEASES; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME; VASCULAR SURGICAL PROCEDURES;

EID: 65749115748     PISSN: 00219509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004;110:738-43.
2. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K et al. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007;115:e69-171.
3. Lange S, Diehm C, Darius H, Haberl R, Allenberg JR, Pittrow D et al. High prevalence of peripheral arterial disease but low antiplatelet treatment rates in elderly primary care patients with diabetes. Diabetes Care 2003;26:3357-8.
4. Jager-Geurts MH PR, van Dis SJ, Bots ML. Cardiovascular diseases in the Netherlands 2006, figures concern disease and mortality. Den Haag: Dutch Heart Foundation, 2006
5. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation 1985;71:510-5.
6. Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991;20:384-92.
7. Leng GC, Lee AJ, Fowkes FG, Whiteman M, Dunbar J, Housley E et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 1996;25:1172-81.
8. Ostchega Y, Paulose-Ram R, Dillon CF, Gu Q, Hughes JP. Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 1999-2004. J Am Geriatr Soc 2007;55:583-9.
9. Meijer WT, Hoes AW, Rutgers D, Bots ML, Holman A, Grobbee DE. Peripheral arterial disease in the elderly: The Rotterdam Study. Arterioscler Thromb Vasc Biol 1998;18:185-92.
10. McDermott MM, Greenland P, Liu K, Guralnik JM, Celic L, Criqui MH et al. The ankle brachial index is associated with leg function and physical activity: the Walking and Leg Circulation Study. Ann Intern Med 2002;136:873-83.
11. Yao ST, Hobbs JT, Irvine WT. Ankle systolic pressure measurements in arterial disease affecting the lower extremities. Br J Surg 1969;56:676-9.
12. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW et al. Peripheral arterial disease detection, awareness, and treatment in primary care. Jama 2001;286:1317-24.
13. Weitz JI, Byrne J, Clagett GP, Farkouh ME, Porter JM, Sackett DL et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 1996;94:3026-49.
14. Menke A, Muntner P, Wildman RP, Dreisbach AW, Raggi P. Relation of borderline peripheral arterial disease to cardiovascular disease risk. Am J Cardiol 2006;98:1226-30.
15. Diehm C, Lange S, Darius H, Pittrow D, von Stritzky B, Tepohl G et al. Association of low ankle brachial index with high mortality in primary care. Eur Heart J 2006;27:1743-9.
16. McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 1991;87:119-28.
17. McDermott MM, Feinglass J, Slavensky R, Pearce WH. The ankle-brachial index as a predictor of survival in patients with peripheral vascular disease. J Gen Intern Med 1994;9:445-9.
18. Resnick HE, Lindsay RS, McDermott MM, Devereux RB, Jones KL, Fabsitz RR et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation 2004;109:733-9.
19. Newman AB, Shemanski L, Manolio TA, Cushman M, Mittelmark M, Polak JF et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol 1999;19:538-45.
20. Leng GC, Fowkes FG, Lee AJ, Dunbar J, Housley E, Ruckley CV. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. Bmj 1996;313:1440-4.
21. Thatipelli MR, Pellikka PA, McBane RD, Rooke TV, Rosales GA, Hodge D et al. Prognostic value of ankle-brachial index and dobutamine stress echocardiography for cardiovascular morbidity and all-cause mortality in patients with peripheral arterial disease. J Vasc Surg 2007; 46:62-70.
22. Quigley FG, Faris IB, Duncan HJ. A comparison of Doppler ankle pressures and skin perfusion pressure in subjects with and without diabetes. Clin Physiol 1991;11:21-5.
23. Mohler ER, 3rd. Peripheral arterial disease: identification and implications. Arch Intern Med 2003;163:2306-14.
24. Vidakovic R, Feringa HH, Kuiper RJ, Karagiannis SE, Schouten O, Dunkelgrun M et al. Comparison with computed tomography of two ultrasound devices for diagnosis of abdominal aortic aneurysm. Am J Cardiol 2007;100:1786-91.
25. Wever JJ, Blankensteijn JD, Th MMWP, Eikelboom BC. Maximal aneurysm diameter follow-up is inadequate after endovascular abdominal aortic aneurysm repair. Eur J Vasc Endovasc Surg 2000;20:177-82.
26. McDermott MM, Greenland P, Liu K, Guralnik JM, Criqui MH, Dolan NC et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA 2001;286:1599-606.
27. Criqui MH, Denenberg JO, Langer RD, Fronek A. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med 1997;2:221-6.
28. Newman AB, Tyrrell KS, Kuller LH. Mortality over four years in SHEP participants with a low ankle-arm index. J Am Geriatr Soc 1997;45:1472-8.
29. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-6.
30. Brevetti G, Schiano V, Verdoliva S, Silvestro A, Sirico G, De Maio J et al. Peripheral arterial disease and cardiovascular risk in Italy. Results of the Peripheral Arteriopathy and Cardiovascular Events (PACE) study. J Cardiovasc Med (Hagerstown) 2oo6;7:608-13.
31. Vogt MT, McKenna M, Wolfson SK, Kuller LH. The relationship between ankle brachial index, other atherosclerotic disease, diabetes, smoking and mortality in older men and women. Atherosclerosis 1993;101:191-202.
32. Aboyans V, Lacroix P, Postil A, Guilloux J, Rolle F, Cornu E et al. Subclinical peripheral arterial disease and incompressible ankle arteries are both long-term prognostic factors in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol 2005;46:815-20.
33. Schmieder FA, Comerota AJ. Intermittent claudication: magnitude of the problem, patient evaluation, and therapeutic strategies. Am J Cardiol 2001;87:3D-13D.
34. Imparato AM, Kim GE, Davidson T, Crowley JG. Intermittent claudication: its natural course. Surgery 1975;78:795-9.
35. Dieter RS, Tomasson J, Gudjonsson T, Brown RL, Vitcenda M, Einerson J et al. Lower extremity peripheral arterial disease in hospitalized patients with coronary artery disease. Vasc Med 2003;8:233-6.
36. Sukhija R, Aronow WS, Yalamanchili K, Sinha N, Babu S. Prevalence of coronary artery disease, lower extremity peripheral arterial disease, and cerebrovascular disease in 110 men with an abdominal aortic aneurysm. Am J Cardiol 2004;94:1358-9.
37. Hertzer NR, Beven EG, Young JR, O'Hara PJ, Ruschhaupt WF, 3rd, Graor RA et al. Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management. Ann Surg 1984;199:223-33.
38. Jamieson WR, Janusz MT, Miyagishima RT, Gerein AN. Influence of ischemic heart disease on early and late mortality after surgery for peripheral occlusive vascular disease. Circulation 1982;66:192-7.
39. Welten GM, Schouten O, Hoeks SE, Chonchol M, Vidakovic R, van Domburg RT et al. Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. J Am Coll Cardiol 2008;51:1588-96.
40. Poredos P, Jug B. The prevalence of peripheral arterial disease in high risk subjects and coronary or cerebrovascular patients. Angiology 2007;58:309-15.
41. Steg PG, Bhatt DL, Wilson PW, D'Agostinc, R, Sr., Ohman EM, Rother J et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007;297:1197-206.
42. Menotti A, Blackburn H, Seccareccia F, Kromhout D, Nissinen A, Aravanis C et al. The relation of chronic diseases to all-cause mortality risk - the Seven Countries Study. Ann Med 1997;29:135-41.
43. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180-9.
44. Lee TH, Marcantonio ER, Mangione CM, Thomas EJ, Polanczyk CA, Cook EF et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999;100:1043-9.
45. Welten GM, Schouten O, van Domburg RT, Feringa HH, Hoeks SE, Dunkelgrun M et al. The influence of aging on the prognostic value of the revised cardiac risk index for postoperative cardiac complications in vascular surgery patients. Eur J Vasc Endovasc Surg 2007;34:632-8.
46. Jude EB, Oyibo SO, Chalmers N, Boulton AJ. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care 2001;24:1433-7.
47. Reiber GE, Pecoraro RE, Koepsell TD. Risk factors for amputation in patients with diabetes mellitus. A case-control study. Ann Intern Med 1992;117:97-105.
48. Dunkelgrun M, Schreiner F, Schockman DB, Hoeks SE, Feringa HH, Goei D et al. Usefulness of preoperative oral glucose tolerance testing for perioperative risk stratificatdon in patients scheduled for elective vascular surgery. Am J Cardiol 2008;101:526-9.
49. Wattanakit K, Folsom AR, Selvin E, Coresh J, Hirsch AT, Weatherley BD. Kidney function and risk of peripheral arterial disease: results from the Atherosclerosis Risk in Communities (ARIC) Study. J Am Soc Nephrol 2007;18:629-36.
50. Welten GM, Chonchol M, Hoeks SE, Schouten O, Bax JJ, Dunkelgrun M et al. Beta-blockers improve outcomes in kidney disease patients having noncardiac vascular surgery. Kidney Int 2007;72:1527-34.
51. van Domburg RT, Hoeks SE, Welten GM, Chonchol M, Elhendy A, Poldermans D. Renal insufficiency and mortality in patients with known or suspected coronary artery disease. J Am Soc Nephrol 2008;19:158-63.
52. Ellenberger C, Schweizer A, Diaper J, Kalangos A, Murith N, Katchatourian G et al. Incidence, risk factors and prognosis of changes in serum creatinine early after aortic abdominal surgery. Intensive Care Med 2006;32:1808-16.
53. Welten GM, Schouten O, Chonchol M, Hoeks SE, Feringa HH, Bax JJ et al. Temporary worsening of renal function after aortic surgery is associated with higher long-term mortality. Am J Kidney Dis 2007;50:219-28.
54. James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P et al. N-terminal pro-brain natriuretic pepticle and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003;108:275-81.
55. Kertai MD, Boersma E, Klein J, Van Urk H, Bax JJ, Poldermans D. Long-term prognostic value of asymptomatic cardiac troponin T elevations in patients after major vascular surgery. Eur J Vasc Endovasc Surg 2004;28:59-66.
56. Baker JF, Schumacher HR, Krishnan E. Serum uric acid level and risk for peripheral arterial disease: analysis of data from the multiple risk factor intervention trial. Angiology 2007;58:450-7.
57. Tsimikas S, Willerson JT, Ricker PM. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol 2006;47:19-31.
58. Du Clos TW. Function of C-reactive protein. Ann Med 2000;32:274-8.
59. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-5.
60. Rossi E, Biasucci LM, Citterio F, Pelliccioni S, Monaco C, Ginnetti F et al. Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: predictive role of C-reactive protein. Circulation 2002;105:800-3.
61. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide, Circulation 2002;105:1760-3.
62. Back MR, Leo F, Cuthbertson D, Johnson BL, Shamesmd ML, Bandyk DF. Long-term survival after vascular surgery: specific influence of cardiac factors and implications for preoperative evaluation. J Vasc Surg 2004;40:752-60.
63. Prault TL, Stevens SL, Freeman MB, Cassada D, Hardin R, Goldman MH. Open versus endo: early experience with endovascular abdominal aortic aneurysm repair beyond the clinical trials. Heart Surg Forum 2004;7:459-61.
64. Schouten O, van Waning VH, Kertai MD, Feringa HH, Bax JJ, Boersma E et al. Perioperative and long-term cardiovascular outcomes in patients undergoing endovascular treatment compared with open vascular surgery for abdominal aortic aneurysm or iliaco-femoro-popliteal bypass. Am J Cardiol 2005;96:861-6.
65. Visser JJ, Bosch JL, Hunink MG, van Dijk LC, Hendriks JM, Poldermans D et al. Endovascular repair versus open surgery in patients with ruptured abdominal aortic aneurysms: clinical outcomes with 1-year follow-up. J Vasc Surg 2006;44:1148-55.
66. Moore WS, Matsumura JS, Makaroun MS, Katzen BT, Deaton DH, Decker M et al. Five-year interim comparison of the Guidant bifurcated endograft with open repair of abdominal aortic aneurysm. J Vasc Surg 2003;38:46-55.
67. McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F et al. Coronary-artery revascularization before elective major vascular surgery. N Engl J Med 2004;351:2795-804.
68. Poldermans D, Schouten O, Vidakovic R, Bax JJ, Thomson IR, Hoeks SE et al. A clinical randomized trial to evaluate the safety of a noninvasive approach in high-risk patients undergoing major vascular surgery: the DECREASE-V Pilot Study. J Am Coll Cardiol 2007;49:1763-9.
69. Rihal CS, Eagle KA, Mickel MC, Foster ED, Sopko G, Gersh BJ. Surgical therapy for coronary artery disease among patients with combined coronary artery and peripheral vascular disease. Circulation 1995;91:46-53.
70. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA 1995;274:975-80.
71. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 2000;31:S1-S296.
72. Juergens JL, Barker NW, Hines EA, Jr. Arteriosclerosis obliterans: review of 520 cases with special reference to pathogenic and prognostic factors. Circulation 1960;21:188-95.
73. Myers KA, King RB, Scott DF, Johnson N, Morris PJ. The effect of smoking on the late patency of arterial reconstructions in the legs. Br J Surg 1978;65:267-71
74. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003;290:86-97.
75. Cifkova R, Erdine S, Fagard R, Farsang C, Heagerty AM, Kiowski W et al. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 2003;21:1779-86.
76. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force Of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Arch Mal Coeur Vaiss 2004;97:1019-30.
77. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005;96:24F-33F.
78. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
79. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.
80. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. Bmj 1994;308:81-106.
81. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001;344:1608-21.
82. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348:1329-39.
83. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989;321:129-35.
84. Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof E, Fleischmann KE et al. ACC/AHA 2006 guideline update on perioperative cardiovascular evaluation for noncardiac surgery: focused update on perioperative beta-blocker therapy: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society for Vascular Medicine and Biology. J Am Coll Cardiol 2006;47:2343-55.
85. Packer M. Current role of beta-adrenergic blockers in the management of chronic heart failure. Am J Med 2001;110:81S-94S.
86. Poldermans D, Boersma E, Bax JJ, Thomson IR, van de Ven LL, Blankensteijn JD et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 1999;341:1789-94.
87. Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB. Use of beta-blockes and the risk of death in hospitalized patients with acute exacerbations of COPD. Thorax 2008;63:301-5.
88. van Gestel YR, Hoeks SE, Sin DD, Welten GM, Schouten O, Witteveen HJ et al. The Impact of Cardioselective Beta-Blockers on Mortality in Patients with COPD and Atherosclerosis. Am J Respir Crit Care Med 2008;178:695-700.
89. Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet 1993;341:1496-500.
90. Welten GM, Chonchol M, Hoeks SE, Schouten O, Dunkelgrun M, van Gestel YR et al. Statin therapy is associated with improved outcomes in vascular surgery patients with renal impairment. Am Heart J 2007;154:954-61.
91. Schouten O, Hoeks SE, Welten GM, Davignon J, Kastelein JJ, Vidakovic R et al. Effect of statin withdrawal on frequency of cardiac events after vascular surgery. Am J Cardiol 2007;100:316-20.
92. Igawa T, Tani T, Chijiwa T, Shiragiku T, Shimidzu S, Kawamura K et al. Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells. Thromb Res 1990;57:617-23.
93. Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, Czerwiec F. Cilostazol as a unique antithrombotic agent. Curr Pharm Des 2003;9:2289-302.
94. Regensteiner JG, Ware JE, Jr., McCarthy WJ, Zhang P, Forbes WP, Heckman J et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc 2002;50:1939-46.
95. Seiffge D. Pentoxifylline: its influence on the interaction of blood cells with the vessel wall. Atherosclerosis 1997;131:S27-8.
96. Porter JM, Cutler BS, Lee BY, Reich T, Reichle FA, Scogin JT et al. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 1982;104:66-72.
97. Ernst E. Pentoxifylline for intermittent claudication. A critical review. Angiology 1994;45:339-45.
98. Reilly DT, Quinton DN, Barrie WW. A controlled trial of pentoxifylline (Trental 400) in intermittent claudication: clinical, haemostatic and rheological effects. N Z Med J 1987;100:445-7.
99. Dawson DL, Cutler BS, Hiatt WR, Hobson RW, 2nd, Martin JD, Bortey EB et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000;109:523-30.
100. McDermott MM, Mehta S, Ahn H, Greenland P. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med 1997;12:209-15.